NeuroMetrix (MUN:NLZ0) - Stock Price, News & Analysis

NLZ0 Stock Overview

A commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China.

About the company

NLZ0 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Risk Analysis

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap (€8M)

Earnings have declined by 16.3% per year over past 5 years

Volatile share price over the past 3 months

+ 1 more risk

NeuroMetrix, Inc. Competitors

Audientes

DB:AUG

€6.9m

aap Implantate

XTRA:AAQ1

€13.0m

Geratherm Medical

XTRA:GME

€21.3m

NanoRepro

XTRA:NN6

€22.8m

Price History & Performance

Summary of all time highs, changes and price drops for NeuroMetrix
Historical stock prices
Current Share Price	US$3.54
52 Week High	US$3.62
52 Week Low	US$2.62
Beta	2.29
11 Month Change	2.31%
3 Month Change	2.31%
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-1.12%

Recent updates

Shareholder Returns

	NLZ0	DE Medical Equipment	DE Market
7D	0%	12.4%	3.1%
1Y	n/a	9.5%	13.3%

Return vs Industry: Insufficient data to determine how NLZ0 performed against the German Medical Equipment industry.

Return vs Market: Insufficient data to determine how NLZ0 performed against the German Market.

Price Volatility

Is NLZ0's price volatile compared to industry and market?
NLZ0 volatility
NLZ0 Average Weekly Movement	7.3%
Medical Equipment Industry Average Movement	5.1%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.4%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: NLZ0's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine NLZ0's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1996	26	Shai Gozani	www.neurometrix.com

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons.

NeuroMetrix, Inc. Fundamentals Summary

How do NeuroMetrix's earnings and revenue compare to its market cap?
NLZ0 fundamental statistics
Market cap	€7.15m
Earnings (TTM)	-€7.13m
Revenue (TTM)	€3.94m

1.8x

P/S Ratio

-1.0x

P/E Ratio

Is NLZ0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NLZ0 income statement (TTM)
Revenue	US$4.38m
Cost of Revenue	US$1.71m
Gross Profit	US$2.67m
Other Expenses	US$10.61m
Earnings	-US$7.94m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-3.92
Gross Margin	60.91%
Net Profit Margin	-181.03%
Debt/Equity Ratio	0%

How did NLZ0 perform over the long term?

See historical performance and comparison

NeuroMetrix MUN:NLZ0 Stock Report